An interventional study of GynMDD and Placebo in Depression, Depression Disorder and Depression in Adults, sponsored by Fondation FondaMental. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Fondation FondaMental · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in Depression with a site in France — 63 open to participants now, 67 under way, 2 of them phase 3. Depression · France.
Among the 266 studies in Depression with a site in France, this one is the 69th largest by planned enrollment of the 185 interventional ones that give a count, is one of 17 that started in 2026, is one of 133 with no phase, reaches primary completion later than 42 of the 66 other live ones, and was the 250th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →63 of the 266 studies in Depression with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
Hospital Ambroise Paré Paris · Sites in France
Ages 18–80
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 7–25
Nantes University Hospital · Sites in France
Ages 18+
Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI) · Sites in France
Ages 18–42 · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 30 · Phase 4 9
First in 1990; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 168 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 120 across the 185 interventional studies, 158 across the 81 observational. Of the 157 that completed or were terminated, 18 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 266 have an industry lead sponsor. The 10 most frequent:
Fondation FondaMental is the lead sponsor of 5 studies on the registry; 5 are open to participants now.
Fondation FondaMental has 1 study filed under Depression — fewer than ten, so there is no comparison to draw.
18 of the studies in Depression with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05632757Assistance Publique Hopitaux De MarseilleAnticipated Patient and Caregiver Burden | 2026-12-22 |
| NCT05074901University of BordeauxVirtual Agents-based Digital Interventions to Improve Health | 2026-12-31 |
| NCT06747793University Hospital, ToulouseVirtual Reality to Reduce the Anxiety in Critically Ill Patient | 2027-01 |
| NCT05661383Hôpital le VinatierOlfactory and Brain Stimulations in Treatment-resistant Depression | 2027-01-27 |
| NCT05149742Assistance Publique - Hôpitaux de ParisDeafness and Cognition in Middle-aged Adults | 2027-05-24 |
Add all 18 to your calendar (.ics) → With an account.
Among the 266 studies in Depression with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether the dietary supplement GynMDD, when taken as an add-on to supportive psychotherapy, can improve symptoms of mild to moderate depression in adults aged 18 to 65. The main questions it aims to answer are:
Does adding GynMDD to supportive psychotherapy lead to a greater reduction in depressive symptoms (measured by the MADRS scale) compared with supportive psychotherapy plus placebo?
Does the supplement also improve digestive well-being and influence gut microbiota profiles over the course of treatment?
Researchers will compare patients receiving supportive psychotherapy + GynMDD to those receiving supportive psychotherapy + placebo to see if GynMDD provides additional benefits beyond standard care.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Supportive Psychotherapy and Dietary Supplement
Dietary Supplement: GynMDD
Supportive Psychotherapy and Placebo
Other: Placebo
Dietary Supplement: GynMDD (Sorolys®) Daily 2.5 g stick for 8 weeks Includes L-glutamine, Cavacurmin®, and Lacticaseibacillus rhamnosus GG
Placebo for 8 weeks Identical stick without active ingredients; β-carotene added for color
Change in MADRS Score
Assessment of depressive symptoms using the Montgomery-Åsberg Depression Rating Scale (MADRS).
Time frame: Baseline (V0) to Week 8 (V2)
Change in Digestive Symptom Score (WGO scale)
Difference in scores on the World Gastroenterology Organization digestive health scale between baseline and follow-up visits.
Time frame: Baseline (V0), Week 4 (V1), Week 8 (V2)
Change in PHQ-9 Self-Reported Depression Score
Weekly PHQ-9 scores completed by participants through the digital platform to assess changes in depressive symptoms.
Time frame: Weekly for 8 weeks
Change in GSRS-IBS Digestive Symptom Score
Weekly GSRS-IBS digestive symptom scores completed on the digital platform.
Time frame: Weekly for 8 weeks
Fecal Microbiota Metagenomic Profile (Shotgun Sequencing)
Presence of predictive microbiota signatures and evolution of gut microbiome composition.
Time frame: Baseline (V0) and Week 8 (V2)
Adverse Events Reporting
Time frame: Weekly until 8 week and at Week 4 (V1), Week 8 (V2)
Proportion of participants requiring initiation of antidepressant therapy
Time frame: Up to Week 8 (V2)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Nov 2027, 20 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 20 months is close to that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondation FondaMental